We then assessed the impact of mTOR on sorafenib resistance in human liver cancer cells by using 3 TSC2-deficient cell lines (SNU886, SNU398 and Li7) and 3 TSC2 WT cell lines (HCCLM3, HepG2 and MHCC97H) (Fig. 1C). Here, TSC2 is linked to liver cancer.